Literature DB >> 16187084

Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.

Koji Tamada1, Lieping Chen.   

Abstract

Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187084     DOI: 10.1007/s00262-005-0081-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

Review 1.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

2.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

3.  Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.

Authors:  Fatih M Uckun; Dorothea E Myers; Sanjive Qazi; Zahide Ozer; Rebecca Rose; Osmond J D'Cruz; Hong Ma
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

4.  Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.

Authors:  Guoqiang Li; Xiaofeng Wu; Feng Zhang; Xiangcheng Li; Beicheng Sun; Yue Yu; Aihong Yin; Lei Deng; Jie Yin; Xuehao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-19       Impact factor: 4.553

5.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

6.  CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.

Authors:  Hidehiko Narazaki; Yuwen Zhu; Liqun Luo; Gefeng Zhu; Lieping Chen
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

7.  Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells.

Authors:  Xiaoping Zhang; Xu Huang; Aria F Olumi
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

8.  Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation.

Authors:  Suman Bandyopadhyay; Meixiao Long; Harry Z Qui; Adam T Hagymasi; Aaron M Slaiby; Marianne A Mihalyo; Hector L Aguila; Robert S Mittler; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice.

Authors:  Deng-Bo Ji; Jia Ye; Yi-Min Jiang; Bo-Wen Qian
Journal:  BMC Complement Altern Med       Date:  2009-07-01       Impact factor: 3.659

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.